PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PAM”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources
PubMed1983

Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: an interim report.

This trial studied the possibility that tamoxifen, added to L-phenylalanine mustard and 5-fluorouracil, enhances the established benefit of the latter two drugs in treatment of women with breast cancer and positive axillary nodes. The addition of tamoxifen resulted in a 25% decrease in treatment failure at 24 months and a 23% decrease at 36 months. In patients greater than or equal to 50 years old, there was a 48% reduction at 24 months and a 39% reduction at 36 months. This advantage was statistically significant at both two and three years' follow-up (p less than 0.001). Higher receptor levels were associated with a greater probability of disease-free survival. Patients less than or equal to 49 years old were less responsive. There was some evidence at 24 months that patients in this age group with four or more positive nodes who also had high ER levels might benefit from tamoxifen. At 36 months, however, this benefit was no longer evident. This form of adjuvant therapy is not recommended in patients less than or equal to 49 years of age whose tumor estrogen and progesterone levels are below 10 fmol; there is an appearance of benefit in patients greater than or equal to 50 with low estrogen and progesterone levels, and stronger evidence of benefit when these levels are high among the older group of patients.

Age Factors↗
PubMed1984

The mitogenic principle of Escherichia coli lipoprotein: B-lymphocyte mitogenicity of the synthetic analogue palmitoyl-tetrapeptide (Pam-Ser-Ser-Asn-Ala).

N-Palmitoyl-(S)-seryl-(S)-seryl-(S)-asparaginyl-(S)-alanine (Palmitoyl-tetrapeptide) is an analogue of the N-terminal part of the lipoprotein from the outer membrane of Escherichia coli. It was prepared by chemical synthesis and tested for biological activity in in vitro lymphocyte culture systems. In spleen cells of the inbred mouse strains C3H/HeJ, C3H/He/Bom/ nunu , and Balb/c, the compound exhibited stimulatory activity towards B-lymphocytes comparable to the effect of native lipoprotein, as measured by the incorporation of 3H-thymidine and 3H-uridine, and by a hemolytic plaque assay. The B-lymphocyte tumor cell line BCL1 was also activated by the compound. The results demonstrate, that the N-terminal tetrapeptide moiety of lipoprotein, linked to a lipophilic molecule, constitutes by itself a novel B-lymphocyte mitogen.

Animals↗
PubMed1990

Use of pralidoxime-Pd(II) complex for the spectrophotometric determination of the cholinesterase reactivator (PAM-2Cl) in the urine.

A simple and rapid method for the spectrophotometric determination of pralidoxime chloride in urine, based on complex formation with palladium(II) without preliminary mineralization of the sample, is described. The proposed method is shown to be reproducible and in good agreement with a reference method, which involved spectrophotometric determination of corresponding oximate ions in ammonium hydroxide solution at 336 nm. Our results indicate that the proposed method is reliable, rapid and of sufficient sensitivity for pralidoxime chloride analysis in urine.

Adult↗